Company: MorphoSys AG
Symbol: MOR
Description: They are a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Their shares are listed on the Frankfurt Stock Exchange under the symbol ‘MOR’.
Trade Date: 4/19
Shares: 8.3 million ADSs
Price Range: $24.12-$24.12
Underwriter(s): Goldman Sachs & Co., J.P. Morgan, Leerink Partners
Co-Manager(s): Berenberg Capital Markets, JMP Securities
Terms Added: 4-9-18
Business: Based on their proprietary technology platforms and leadership in the field of therapeutic antibody discovery, generation and engineering, they, together with their partners, have participated in the development of more than 100 therapeutic product candidates. Their broad pipeline spans two business segments: Proprietary Development, in which they invest in and develop product candidates, and Partnered Discovery, in which they generate product candidates for their partners in the pharmaceutical and biotechnology industries against targets identified by their partners. They currently have 28 product candidates in clinical development, including their most advanced proprietary product candidate, MOR208, for the treatment of relapsed or refractory diffuse large B cell lymphoma, or r/r DLBCL. They believe their pipeline of novel and differentiated product candidates has the potential to treat serious diseases and improve the lives of patients.
Their late-stage and most advanced proprietary product candidate, MOR208, received breakthrough therapy designation, or BTD, from the U.S. Food and Drug Administration, or the FDA, in 2017 in combination with lenalidomide for the treatment of patients with r/r DLBCL, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation. They hold worldwide rights to develop and market MOR208. Also in 2017, Tremfya®, developed by their partner Janssen, became the first therapeutic antibody based on their proprietary technology to reach the market. Tremfya®, which is approved to treat moderate-to-severe plaque psoriasis, was launched in the United States in July 2017 and received approval for marketing in the European Union and Canada in November 2017.
Collaborations: This healthcare company has collaborations with Celgene, Janssen and Galapagos. Additionally, this company has one of their drugs being developed by Roche.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish